Etidronate, calcium, or both did not reduce fracture rates in patients with asthma receiving glucocorticoid treatment.

نویسنده

  • Sophie A Jamal
چکیده

MAIN RESULTS The groups did not differ for mortality (10%, 24%, 16%, and 16% in the etidronate only, calcium only, etidronate plus calcium, and no treatment groups, respectively); symptomatic fractures (6%, 8%, 10%, and 7%, respectively); or symptomatic fractures, semi quantitative vertebral fractures, or both (16%, 18%, 16%, and 20%, respectively). Groups receiving etidronate compared with groups not receiving etidronate, and groups receiving calcium compared with groups not receiving calcium, did not differ for rates of any fractures, respectively (table).

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Five year study of etidronate and/or calcium as prevention and treatment for osteoporosis and fractures in patients with asthma receiving long term oral and/or inhaled glucocorticoids.

BACKGROUND Glucocorticoids are associated with a reduction in bone density and an increased risk of fracture. Concurrent treatment with bisphosphonates reduces bone loss and may prevent fractures. A randomised study was performed to determine whether treatment with cyclical etidronate and/or calcium for 5 years prevents fractures or reverses/reduces bone loss in patients receiving glucocorticoi...

متن کامل

Calcium, vitamin D and etidronate for the prevention and treatment of corticosteroid-induced osteoporosis in patients with rheumatic diseases.

INTRODUCTION Long-term glucocorticoid therapy, a major risk factor for the development of osteoporosis, is often necessary in chronically ill patients. At present there are no generally accepted guidelines for the prevention or treatment of steroid-induced osteoporosis. METHODS In an open prospective study we investigated 99 patients with chronic rheumatic diseases receiving > or = 5 mg/day o...

متن کامل

Bisphosphonates and glucocorticoid-induced osteoporosis: implications for patients with respiratory diseases.

Osteoporosis is a well known consequence of glucocorti-coid treatment that can result in significant morbidity and mortality. Glucocorticoid-induced bone loss occurs early, usually within 6–12 months of starting therapy. During this time the rate of bone loss is rapid before decreasing or reaching a plateau. 1 2 4 Clinically this decrease in bone mineral density puts patients at an increased ri...

متن کامل

Alendronate-Related Femoral Fracture in a premenopausal glucocorticoid treated patient

Abstract Background: Alendronate is a bisphosphonate that is approved to reduce bone loss in glucocorticoid treated patients. In this paper, we present a case of femoral fracture following the use of Alendronate. Case presentation: A- 46 year old woman who was a known case of hemolytic anemia has been treated by prednisolone (with different doses from 7.5 to 75 mg/day), calcium-D 500 mg/day a...

متن کامل

Different Gene Expressions of Alpha and Beta Glucocorticoid Receptors in Asthmatics

The response to glucocorticoids (GCs) therapy classifies severe refractory asthma (SRA) and mild asthma, so the glucocorticoid receptors (GCRs) gene expression may be involved in SRA pathogenesis. Thus, it is aimed to compare the expression levels of two GCR isoforms (GCRα and GCRβ) in SRA, mild asthmatics, and healthy controls. Total RNA was isolated from the peripheral blood mononuclear lymph...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:
  • ACP journal club

دوره 142 2  شماره 

صفحات  -

تاریخ انتشار 2005